Delta-like ligand 4 (Dll4) predicts the prognosis of clear cell renal cell carcinoma, and anti-Dll4 suppresses tumor growth in vivo

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 5, 2014, Pages 2143-2152

  Hu, Guang Hui ^a   Liu, Huan ^a   Lai, Peng ^a   Guo, Zhui Feng ^a   Xu, Liang ^a   Yao, Xu Dong ^a   Zheng, Jun Hua ^a   Liu, Min ^a   Xu, Yun Fei ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Angiogenesis; Anti Dll4; Clear cell renal cell carcinoma; Delta like ligand 4; Prognosis; Tumor growth

Indexed keywords

DLL4 PROTEIN, HUMAN; SIGNAL PEPTIDE; SMALL INTERFERING RNA; TUMOR MARKER;

AGED; ANIMAL; CARCINOMA, RENAL CELL; CELL PROLIFERATION; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; HUMAN; KIDNEY NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; RNA INTERFERENCE; SECONDARY; TIME; TUMOR CELL LINE; TUMOR VOLUME;

AGED; ANIMALS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; MALE; MICE, NUDE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TIME FACTORS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902477283     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Fiuza UM and Arias AM. Cell and molecular biology of Notch. J Endocrinol 2007; 194: 459-474.
2. Guruharsha KG, Kankel MW and Artavanis-Tsakonas S. The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet 2012; 13: 654-666.
3. Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell 2009; 16: 633-647.
4. .
5. Brzozowa M, Mielanczyk L, Michalski M, Malinowski L, Kowalczyk-Ziomek G, Helewski K, Harabin-Slowinska M and Wojnicz R. Role of Notch signaling pathway in gastric cancer pathogenesis. Contemp Oncol (Pozn) 2013; 17: 1-5.
6. Sjolund J, Bostrom AK, Lindgren D, Manna S, Moustakas A, Ljungberg B, Johansson M, Fredlund E and Axelson H. The notch and TGF-beta signaling pathways contribute to the aggressiveness of clear cell renal cell carcinoma. PLoS One 2011; 6: e23057.
7. Miyamoto S and Rosenberg DW. Role of Notch signaling in colon homeostasis and carcinogenesis. Cancer Sci 2011; 102: 1938-1942.
8. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, Singh M, Chien M, Tan C, Hongo JA, de Sauvage F, Plowman G and Yan M. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006; 444: 1083-1087.
9. Phng LK and Gerhardt H. Angiogenesis: a team effort coordinated by notch. Dev Cell 2009; 16: 196-208.
10. Swift MR and Weinstein BM. Arterial-venous specification during development. Circ Res 2009; 104: 576-588.
11. Gale NW, Dominguez MG, Noguera I, Pan L, Hughes V, Valenzuela DM, Murphy AJ, Adams NC, Lin HC, Holash J, Thurston G and Yancopoulos D. Haploinsufficiency of delta-like 4 ligand results in embryonic lethality due to major defects in arterial and vascular development. Proc Natl Acad Sci U S A 2004; 101: 15949-15954.
12. Patel NS, Li JL, Generali D, Poulsom R, Cranston DW and Harris AL. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 2005; 65: 8690-8697.
13. Patel NS, Dobbie MS, Rochester M, Steers G, Poulsom R, Le Monnier K, Cranston DW, Li JL and Harris AL. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res 2006; 12: 4836-4844.
14. Stewart KS, Zhou Z, Zweidler-McKay P and Kleinerman ES. Delta-like ligand 4-Notch signaling regulates bone marrow-derived pericyte/vascular smooth muscle cell formation. Blood 2011; 117: 719-726.
15. Cohen HT and McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477-2490.
16. Park K, Lee JL, Park I, Park S, Ahn Y, Ahn JH, Ahn S, Song C, Hong JH, Kim CS and Ahn H. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI. Med Oncol 2012; 29: 3291-3297.
17. Kang M, Jiang B, Xu B, Lu W, Guo Q, Xie Q, Zhang B, Dong X, Chen D and Wu Y. Delta like ligand 4 induces impaired chemo-drug delivery and enhanced chemoresistance in pancreatic cancer. Cancer Lett 2013; 330: 11-21.
18. Watson O, Novodvorsky P, Gray C, Rothman AM, Lawrie A, Crossman DC, Haase A, McMahon K, Gering M, Van Eeden FJ and Chico TJ. Blood flow suppresses vascular Notch signalling via dll4 and is required for angiogenesis in response to hypoxic signalling. Cardiovasc Res 2013; 100: 252-261.
19. Mailhos C, Modlich U, Lewis J, Harris A, Bicknell R, Ish-Horowicz D. Delta4, an endothelial specific Notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 2001; 69: 135-144.
20. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD and Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Novartis Found Symp 2007; 283: 106-120; discussion 121-105, 238-141.
21. Jubb AM, Turley H, Moeller HC, Steers G, Han C, Li JL, Leek R, Tan EY, Singh B, Mortensen NJ, Noguera-Troise I, Pezzella F, Gatter KC, Thurston G, Fox SB and Harris AL. Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. Br J Cancer 2009; 101: 1749-1757.
22. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, Biswas S, Turley H, Heikamp E, Hainfellner JA and Harris AL. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 2007; 67: 11244-11253.
23. Zhang JX, Cai MB, Wang XP, Duan LP, Shao Q, Tong ZT, Liao DZ, Li YY, Huang MY, Zeng YX and Shao JY. Elevated DLL4 expression is correlated with VEGF and predicts poor prognosis of nasopharyngeal carcinoma. Med Oncol 2013; 30: 390.
24. Chen HT, Cai QC, Zheng JM, Man XH, Jiang H, Song B, Jin G, Zhu W and Li ZS. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer. Ann Surg Oncol 2012; 19 Suppl 3: S464-474.
25. Jubb AM, Soilleux EJ, Turley H, Steers G, Parker A, Low I, Blades J, Li JL, Allen P, Leek R, Noguera-Troise I, Gatter KC, Thurston G and Harris AL. Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer. Am J Pathol 2010; 176: 2019-2028.
26. Scehnet JS, Jiang W, Kumar SR, Krasnoperov V, Trindade A, Benedito R, Djokovic D, Borges C, Ley EJ, Duarte A and Gill PS. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 2007; 109: 4753-4760.
27. Thurston G, Noguera-Troise I and Yancopoulos GD. The Delta paradox: DLL4 blockade leads to more tumour vessels but less tumour growth. Nat Rev Cancer 2007; 7: 327-331.
28. Krebs LT, Xue YZ, Norton CR, Shutter JR, Maguire M, Sundberg JP, Gallahan D, Closson V, Kitajewski J, Callahan R, Smith GH, Stark KL and Gridley T. Notch signaling is essential for vascular morphogenesis in mice. Genes Dev 2000; 14: 1343-1352.
29. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen YM, Finkle D, Venook R, Wu XM, Ridgway J, Schahin-Reed D, Dow GJ, Shelton A, Stawicki S, Watts RJ, Zhang J, Choy R, Howard P, Kadyk L, Yan MH, Zha JP, Callahan CA, Hymowitz SG and Siebel CW. Therapeutic antibody targeting of individual Notch receptors. Nature 2010; 464: 1052-1057.
30. Schadler KL, Zweidler-McKay PA, Guan H and Kleinerman ES. Delta-like ligand 4 plays a critical role in pericyte/vascular smooth muscle cell formation during vasculogenesis and tumor vessel expansion in Ewing's sarcoma. Clin Cancer Res 2010; 16: 848-856.
31. Lawson ND, Vogel AM and Weinstein BM. sonic hedgehog and vascular endothelial growth factor act upstream of the notch pathway during arterial endothelial differentiation. Dev Cell 2002; 3: 127-136.
32. Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, Fairman RM, Velazquez OC and Herlyn M. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: Implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 2003; 23: 14-25.
33. Yen WC, Fischer MM, Hynes M, Wu J, Kim E, Beviglia L, Yeung VP, Song X, Kapoun AM, Lewicki J, Gurney A, Simeone DM and Hoey T. Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells. Clin Cancer Res 2012; 18: 5374-5386.
34. Liu SK, Bham SA, Fokas E, Beech J, Im J, Cho S, Harris AL and Muschel RJ. Delta-like ligand 4-notch blockade and tumor radiation response. J Natl Cancer Inst 2011; 103: 1778-1798.
35. Jenkins DW, Ross S, Veldman-Jones M, Foltz IN, Clavette BC, Manchulenko K, Eberlein C, Kendrew J, Petteruti P, Cho S, Damschroder M, Peng L, Baker D, Smith NR, Weir HM, Blakey DC, Bedian V and Barry ST. MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo. Mol Cancer Ther 2012; 11: 1650-1660.
36. Kuramoto T, Goto H, Mitsuhashi A, Tabata S, Ogawa H, Uehara H, Saijo A, Kakiuchi S, Maekawa Y, Yasutomo K, Hanibuchi M, Akiyama S, Sone S and Nishioka Y. Dll4-Fc, an Inhibitor of Dll4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-kappa B Activity. Mol Cancer Ther 2012; 11: 2578-2587.
37. Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R, Jacobs RT, Zacco A, Greenberg B and Ciaccio PJ. Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 2004; 82: 341-358.